Joincare Pharmaceutical Group IndustryLtd Future Growth

Future criteria checks 1/6

Joincare Pharmaceutical Group IndustryLtd is forecast to grow earnings and revenue by 11.8% and 8.3% per annum respectively. EPS is expected to grow by 11.9% per annum. Return on equity is forecast to be 10.7% in 3 years.

Key information

11.8%

Earnings growth rate

11.9%

EPS growth rate

Pharmaceuticals earnings growth	19.4%
Revenue growth rate	8.3%
Future return on equity	10.7%
Analyst coverage	Low
Last updated	28 Oct 2024

Recent future growth updates

No updates

Recent updates

Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

Aug 13

We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Jun 23

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

May 31

Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Apr 09

Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

Mar 04

Earnings and Revenue Growth Forecasts

SHSE:600380 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	19,372	1,921	N/A	4,256	3
12/31/2025	18,318	1,694	N/A	3,893	4
12/31/2024	16,963	1,528	N/A	4,387	4
9/30/2024	15,894	1,471	2,969	4,083	N/A
6/30/2024	16,161	1,404	3,286	4,409	N/A
3/31/2024	16,427	1,420	3,519	4,653	N/A
12/31/2023	16,646	1,443	2,799	3,929	N/A
9/30/2023	16,782	1,460	2,903	3,829	N/A
6/30/2023	17,298	1,517	2,383	3,332	N/A
3/31/2023	17,044	1,505	2,239	3,354	N/A
12/31/2022	17,143	1,503	2,830	3,978	N/A
9/30/2022	16,982	1,446	2,014	3,551	N/A
6/30/2022	16,633	1,442	2,057	3,720	N/A
3/31/2022	16,416	1,422	1,468	2,940	N/A
12/31/2021	15,904	1,328	1,042	2,563	N/A
9/30/2021	15,352	1,202	1,387	2,662	N/A
6/30/2021	14,881	1,132	1,369	2,522	N/A
3/31/2021	14,479	1,207	2,005	3,037	N/A
12/31/2020	13,522	1,120	2,195	3,025	N/A
9/30/2020	12,792	1,043	1,813	2,515	N/A
6/30/2020	12,171	1,024	1,785	2,430	N/A
3/31/2020	11,826	869	1,564	2,239	N/A
12/31/2019	11,980	894	1,609	2,312	N/A
9/30/2019	11,858	837	1,949	2,614	N/A
6/30/2019	11,741	820	2,055	2,701	N/A
3/31/2019	11,536	779	1,445	2,059	N/A
12/31/2018	11,204	699	1,171	1,826	N/A
9/30/2018	11,208	749	940	1,593	N/A
6/30/2018	11,083	2,232	N/A	1,518	N/A
3/31/2018	11,030	2,167	N/A	1,790	N/A
1/1/2018	10,779	2,133	N/A	1,870	N/A
9/30/2017	10,562	2,103	N/A	1,690	N/A
6/30/2017	10,254	521	N/A	1,713	N/A
3/31/2017	10,125	484	N/A	1,779	N/A
12/31/2016	9,722	451	N/A	1,645	N/A
9/30/2016	9,546	346	N/A	1,699	N/A
6/30/2016	9,373	337	N/A	1,388	N/A
3/31/2016	8,881	393	N/A	1,354	N/A
12/31/2015	8,642	412	N/A	1,265	N/A
9/30/2015	8,317	492	N/A	1,132	N/A
6/30/2015	8,031	487	N/A	1,125	N/A
3/31/2015	7,802	412	N/A	968	N/A
12/31/2014	7,418	354	N/A	979	N/A
9/30/2014	7,413	319	N/A	700	N/A
6/30/2014	6,869	298	N/A	604	N/A
3/31/2014	6,463	282	N/A	717	N/A
12/31/2013	6,220	274	N/A	636	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600380's forecast earnings growth (11.8% per year) is above the savings rate (2.8%).

Earnings vs Market: 600380's earnings (11.8% per year) are forecast to grow slower than the CN market (26.3% per year).

High Growth Earnings: 600380's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600380's revenue (8.3% per year) is forecast to grow slower than the CN market (14% per year).

High Growth Revenue: 600380's revenue (8.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600380's Return on Equity is forecast to be low in 3 years time (10.7%).

Joincare Pharmaceutical Group IndustryLtd Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.14 in 3Q 2023)

Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380) announces an Equity Buyback for CNY 500 million worth of its shares.

Investor sentiment improves as stock rises 24%

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 2Q 2023)

Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

Dividend of CN¥0.18 announced

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

Joincare Pharmaceutical Group Industry Co.,Ltd., Annual General Meeting, Jun 07, 2024

First quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in 1Q 2023)

Joincare Pharmaceutical Successfully Completes TG-1000 Phase III Study

Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS exceeds analyst expectations

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

Investor sentiment improves as stock rises 15%

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 03, 2024

Now 22% undervalued after recent price drop

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.18 in 2Q 2022)

New minor risk - Shareholder dilution

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2023 Results on Aug 24, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380) commences an Equity Buyback for CNY 600 million worth of its shares, under the authorization approved on November 18, 2022.

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.16 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 2Q 2021)

Less than half of directors are independent

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.20 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.57 (vs CN¥0.46 in FY 2019)

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥12.67

New 90-day low: CN¥13.96

New 90-day low: CN¥14.59

Third quarter earnings released

New 90-day low: CN¥16.46

First half earnings released

Joincare Pharmaceutical Group Industry Co.,Ltd. announced that it expects to receive CNY 2.1727605 billion in funding from Hillhouse Capital Management, Ltd.

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies